Published in Nat Med on December 08, 2014
Germline De Novo Mutations in GNB1 Cause Severe Neurodevelopmental Disability, Hypotonia, and Seizures. Am J Hum Genet (2016) 0.91
Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms. Mol Cancer (2015) 0.82
The G protein Gαs acts as a tumor suppressor in sonic hedgehog signaling-driven tumorigenesis. Cell Cycle (2016) 0.78
Genetic wiring maps of single-cell protein states reveal an off-switch for GPCR signalling. Nature (2017) 0.78
Oncogenes: nothing but a G thing. Nat Rev Cancer (2015) 0.75
PREX1 integrates G protein-coupled receptor and phosphoinositide 3-kinase signaling to promote glioblastoma invasion. Oncotarget (2016) 0.75
The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells. Oncotarget (2015) 0.75
Direct Calculation of Protein Fitness Landscapes through Computational Protein Design. Biophys J (2016) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Discovery and saturation analysis of cancer genes across 21 tumour types. Nature (2014) 11.68
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42
Lessons from the cancer genome. Cell (2013) 8.12
The structure of the G protein heterotrimer Gi alpha 1 beta 1 gamma 2. Cell (1995) 7.66
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol (2008) 5.30
Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits. Nature (1994) 4.05
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia (2013) 3.93
A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein beta gamma subunits. Cell (1994) 3.50
A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature (2013) 3.38
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell (2013) 3.13
Molecular basis for interactions of G protein betagamma subunits with effectors. Science (1998) 2.88
Isozyme-selective stimulation of phospholipase C-beta 2 by G protein beta gamma-subunits. Nature (1992) 2.88
Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia (2013) 2.85
Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med (2006) 2.69
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet (2010) 2.47
The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer (2013) 2.05
Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res (2012) 2.01
mzAPI: a new strategy for efficiently sharing mass spectrometry data. Nat Methods (2009) 1.68
Magnetic bead processor for rapid evaluation and optimization of parameters for phosphopeptide enrichment. Anal Chem (2009) 1.65
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med (2012) 1.65
Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature (1988) 1.52
Transforming G proteins. Oncogene (2001) 1.46
multiplierz: an extensible API based desktop environment for proteomics data analysis. BMC Bioinformatics (2009) 1.41
Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. Leukemia (2013) 1.17
Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype. Haematologica (2009) 1.17
Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. Blood (2011) 1.12
Analysis of the fibroblast transformation potential of GTPase-deficient gip2 oncogenes. Mol Cell Biol (1992) 1.09
Online nanoflow multidimensional fractionation for high efficiency phosphopeptide analysis. Mol Cell Proteomics (2011) 1.02
The complete peptide dictionary--a meta-proteomics resource. Proteomics (2010) 1.01
The role of the GPR91 ligand succinate in hematopoiesis. J Leukoc Biol (2009) 0.99
Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2. Blood (2012) 0.97
DNA ends alter the molecular composition and localization of Ku multicomponent complexes. Mol Cell Proteomics (2012) 0.96
Lymphoid organ-resident dendritic cells exhibit unique transcriptional fingerprints based on subset and site. PLoS One (2011) 0.86
Chaperone-mediated assembly of G protein complexes. Subcell Biochem (2012) 0.84
Next-generation cDNA screening for oncogene and resistance phenotypes. PLoS One (2012) 0.80
Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013) 2.12
Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet (2014) 1.67
Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nat Genet (2016) 1.57
Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nat Biotechnol (2016) 0.82
Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet (2016) 0.80
Aggressive Langerhans cell histiocytosis following T-ALL: clonally related neoplasms with persistent expression of constitutively active NOTCH1. Am J Hematol (2008) 0.75
Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia. Nat Immunol (2016) 0.75